State of Practice: ASNR Statement on Gadolinium-Based Contrast Agent Use in Patients with Chronic Kidney Disease

Kirk M. Welker; David Joyner; Anthony W. Kam; David S. Liebeskind; Amit M. Saindane; Colin Segovis; Noushin Yahyavi-Firouz-Abadi; John E. Jordan

doi:10.3174/ajnr.A8501

Main menu

Home
Content
Special Collections
Multimedia
For Authors
About Us
More

User menu

Alerts
Log in

Search

Search for this keyword

Advanced search

American Journal of Neuroradiology

Alerts
Log in

Search for this keyword

Advanced Search

Home
Content
Special Collections
Multimedia
For Authors
About Us
More

Follow AJNR on Twitter
Visit AJNR on Facebook
Follow AJNR on Instagram
Join AJNR on LinkedIn
RSS Feeds

AJNR Awards, New Junior Editors, and more. Read the latest AJNR updates

State Of PracticeHealth Policies/Quality Improvement/Evidence-Based Neuroimaging

State of Practice: ASNR Statement on Gadolinium-Based Contrast Agent Use in Patients with Chronic Kidney Disease

Kirk M. Welker, David Joyner, Anthony W. Kam, David S. Liebeskind, Amit M. Saindane, Colin Segovis, Noushin Yahyavi-Firouz-Abadi and John E. Jordan

American Journal of Neuroradiology February 2025, 46 (2) 227-230; DOI: https://doi.org/10.3174/ajnr.A8501

Kirk M. Welker

aFrom the Department of Radiology (K.M.W.), Mayo Clinic, Rochester, Minnesota

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Kirk M. Welker

David Joyner

bDepartment of Radiology and Medical Imaging (D.J.), University of Virginia, Charlottesville, Virginia

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for David Joyner

Anthony W. Kam

cDepartment of Radiology (A.W.K.), Loyola University Medical Center, Maywood, Illinois

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Anthony W. Kam

David S. Liebeskind

dDepartment of Neurology (D.S.L.), University of California Los Angeles, Los Angeles, California

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for David S. Liebeskind

Amit M. Saindane

eDepartment of Radiology and Imaging Sciences (A.M.S., C.S.), Emory University School of Medicine, Atlanta, Georgia

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Amit M. Saindane

Colin Segovis

eDepartment of Radiology and Imaging Sciences (A.M.S., C.S.), Emory University School of Medicine, Atlanta, Georgia

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Colin Segovis

Noushin Yahyavi-Firouz-Abadi

fDepartment of Radiology and Nuclear Medicine (N.Y.-F.-A.), University of Maryland School of Medicine, Baltimore, Maryland

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Noushin Yahyavi-Firouz-Abadi

John E. Jordan

gDepartment of Radiology (J.E.J.), Providence Little Company of Mary Medical Center, Torrance, California

hChair ASNR Standards and Guidelines Committee (J.E.J.)

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for John E. Jordan

Article
Figures & Data
Supplemental
Info & Metrics
Responses
References
PDF

Article Figures & Data

Figures

Tables

Download figure
Open in new tab
Download powerpoint

Tables

Figures

Gadolinium-based contrast agents by ACR groups¹¹

ACR Group	Generic Name	Product Name(s)	Chemical Structure	3T Relaxivity
I	Gadopentetate dimeglumine	Magnevist (Bayer)	Linear/ionic	3.7
I	Gadodiamide	Omniscan (GE HealthCare)	Linear/nonionic	4
I	Gadoversetamide	Optimark (Guerbet)	Linear/nonionic	4.5
II	Gadobenate dimeglumine	Multihance (Bracco)	Linear/ionic	5.5
II	Gadoterate meglumine	Clariscan (GE HealthCare), Dotarem (Guerbet)	Macrocyclic/ionic	3.5
II	Gadobutrol	Gadavist (Bayer), Gadovost (Bayer)	Macrocyclic/nonionic	5
II	Gadoteridol	Prohance (Bracco)	Macrocyclic/nonionic	3.7
II	Gadopiclenol	Elucirem (Guerbet), Vueway (Bracco)	Macrocyclic/nonionic	11.6
II	Gadoxetate disodium	Eovist (Bayer), Primovist (Bayer)	Linear/ionic	6.2

PreviousNext

In this issue

American Journal of Neuroradiology

Vol. 46, Issue 2

1 Feb 2025

Table of Contents
Index by author
Complete Issue (PDF)

Download PDF

Email Article

Thank you for your interest in spreading the word on American Journal of Neuroradiology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following State of Practice: ASNR Statement on Gadolinium-Based Contrast Agent Use in Patients with Chronic Kidney Disease

Message Subject (Your Name) has sent you a message from American Journal of Neuroradiology

Message Body (Your Name) thought you would like to see the American Journal of Neuroradiology web site.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Cite this article

Kirk M. Welker, David Joyner, Anthony W. Kam, David S. Liebeskind, Amit M. Saindane, Colin Segovis, Noushin Yahyavi-Firouz-Abadi, John E. Jordan

State of Practice: ASNR Statement on Gadolinium-Based Contrast Agent Use in Patients with Chronic Kidney Disease

American Journal of Neuroradiology Feb 2025, 46 (2) 227-230; DOI: 10.3174/ajnr.A8501

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

0 Responses

Respond to this article

Bookmark this article

User Name *

Password *

Remember my user name & password.

ASNR Gadolinium Contrast Use in CKD Patients

Kirk M. Welker, David Joyner, Anthony W. Kam, David S. Liebeskind, Amit M. Saindane, Colin Segovis, Noushin Yahyavi-Firouz-Abadi, John E. Jordan

American Journal of Neuroradiology Feb 2025, 46 (2) 227-230; DOI: 10.3174/ajnr.A8501

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Purchase

Jump to section

Article
Figures & Data
Supplemental
Info & Metrics
Responses
References
PDF

PubMed
Google Scholar

Cited By...

No citing articles found.

Crossref
Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

Indexed Content

Current Issue
Accepted Manuscripts
Article Preview
Past Issues
Editorials
Editor's Choice
Fellows' Journal Club
Letters to the Editor
Video Articles

Cases

Case Collection
Archive - Case of the Week
Archive - Case of the Month
Archive - Classic Case

Multimedia

AJNR Podcasts
AJNR Scantastics

Resources

Turnaround Time
Submit a Manuscript
Submit a Video Article
Submit an eLetter to the Editor/Response
Manuscript Submission Guidelines
Statistical Tips
Fast Publishing of Accepted Manuscripts
Graphical Abstract Preparation
Imaging Protocol Submission
Evidence-Based Medicine Level Guide
Publishing Checklists
Author Policies
Become a Reviewer/Academy of Reviewers
News and Updates

About Us

About AJNR
Editorial Board
Editorial Board Alumni
Alerts
Permissions
Not an AJNR Subscriber? Join Now
Advertise with Us
Librarian Resources
Feedback
Terms and Conditions
AJNR Editorial Board Alumni

American Society of Neuroradiology

Not an ASNR Member? Join Now

Main menu

User menu

Search

American Journal of Neuroradiology

State of Practice: ASNR Statement on Gadolinium-Based Contrast Agent Use in Patients with Chronic Kidney Disease

Article Figures & Data

Figures

Tables

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Indexed Content

Cases

More from AJNR

Multimedia

Resources

About Us

American Society of Neuroradiology